Please use this identifier to cite or link to this item:
Title: The prognostic impact of minimal residual disease in patients with chronic lymphocytic leukemia requiring first-line therapy.
Author: Santacruz, Rodrigo
Villamor i Casas, Neus
Aymerich Gregorio, Marta
Martínez Trillos, Alejandra
López, Cristina
Navarro López, Alba
Rozman, María
Beà Bobet, Sílvia M.
Royo Moreno, Cristina
Cazorla, Maite
Colomer Pujol, Dolors
Giné Soca, Eva
Pinyol, Magda
Puente, Xose S.
López-Otin, Carlos
Campo Güerri, Elias
López Guillermo, Armando
Delgado, Julio (Delgado González)
Keywords: Leucèmia limfocítica crònica
Biologia molecular
Chronic lymphocytic leukemia
Molecular biology
Issue Date: May-2014
Publisher: Ferrata Storti Foundation
Abstract: A proportion of patients with chronic lymphocytic leukemia achieve a minimal residual disease negative status after therapy. We retrospectively evaluated the impact of minimal residual disease on the outcome of 255 consecutive patients receiving any front-line therapy in the context of a detailed prognostic evaluation, including assessment of IGHV, TP53, NOTCH1 and SF3B1 mutations. The median follow-up was 73 months (range, 2-202) from disease evaluation. The median treatment-free survival durations for patients achieving a complete response without or with minimal residual disease, a partial response and no response were 76, 40, 11 and 11 months, respectively (P<0.001). Multivariate analysis revealed that three variables had a significant impact on treatment-free survival: minimal residual disease (P<0.001), IGHV status (P<0.001) and β2-microglobulin levels (P=0.012). With regards to overall survival, factors predictive of an unfavorable outcome were minimal residual disease positivity (P=0.014), together with advanced age (P<0.001), unmutated IGHV status (P=0.001), TP53 mutations (P<0.001) and elevated levels of β2-microglobulin (P=0.003). In conclusion, for patients requiring front-line therapy, achievement of minimal residual disease negativity is associated with significantly prolonged treatment-free and overall survival irrespective of other prognostic markers or treatment administered.
Note: Reproducció del document publicat a:
It is part of: Haematologica, 2014, vol. 99, num. 5, p. 873-880
Related resource:
ISSN: 0390-6078
Appears in Collections:Articles publicats en revistes (IDIBAPS: Institut d'investigacions Biomèdiques August Pi i Sunyer)
Articles publicats en revistes (Fonaments Clínics)

Files in This Item:
File Description SizeFormat 
646638.pdf891.48 kBAdobe PDFView/Open

Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.